EP0692483A4 — CELL ADHESION INHIBITOR AND THIENOTRIAZOLODIAZEPINE-BASED COMPOUND
Assigned to Tanabe Pharma Corp · Expires 1995-11-29 · 30y expired
What this patent protects
A thienotriazolodiazepine compound such as N-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl))-N'-(2-methoxyphenyl)urea, an optically active isomer or a pharmaceutically acceptable salt thereof, and a cell adhesion inhibitor comprising…
USPTO Abstract
A thienotriazolodiazepine compound such as N-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl))-N'-(2-methoxyphenyl)urea, an optically active isomer or a pharmaceutically acceptable salt thereof, and a cell adhesion inhibitor comprising said compound as the active ingredient. This compound has the effect of inhibiting cell adhesion and hence is expected to be useful in the prevention and treatment of, for example, various inflammatory diseases, allergic diseases and articular rheumatism in the onset and progress of which cell adhesion participates. Further, it is usable for preventing and treating autoimmune diseases and rejection reactions accompanying organ transplantation and, furthermore, for preventing the metastasis of tumor cells.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.